Additionally, the FDA approved arthritis treatment auranofin (AF, Ridaura®) is known to inhibit the selenoproteins thioredoxin reductase (TXNRD1) and GPX1 with emerging potential as an anti-cancer agent [6,41,42]. This evidence concerns the gene GPX1 and cancer.